Ildong to market Niaspanor in Korea

Published: 2009-09-30 06:57:00

Updated: 2009-09-30 06:57:00

Ildong Pharm and Abbott Korea has recently announced that the two companies have signed an agreement to let Ildong Pharm market Niaspanor (nicotinic acid) as an exclusive basis here, while Abbott Korea retains its license and marketing right.

Prolonged release nicotinic acid was mentioned as a...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK